France neuroendocrine tumor therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.
France Neuroendocrine Tumor Therapeutics Market is valued at around $53.9 Mn in 2022 and is projected to reach $112.23 Mn by 2030, exhibiting a CAGR of 9.6% during the forecast period 2023-2030.
Cancers known as neuroendocrine tumors start in specialized cells known as neuroendocrine cells. Nerve and hormone-producing cells share characteristics with neuroendocrine cells. Neuroendocrine tumors are rare and can grow anywhere in the body. The rectum, appendix, small intestine, lungs, and pancreas are where most neuroendocrine tumors are born. The precise cause of neuroendocrine tumors is uncertain. These cancers begin in neuroendocrine cells, which share traits with neuronal and hormone-producing cells. Neuroendocrine cells abound throughout your body.
The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Also, other drivers of this market expansion are the release of five new pipeline agents, label expansions for already approved agents, or entry into new markets. The increased prevalence of narcoleptic disorders worldwide, rising stress levels, an aging population, and growing public awareness of the variety of treatments for this condition are all predicted to have a positive impact on the market. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.
Market Growth Drivers
The rapidly rising incidence of neuroendocrine carcinoma, expanding therapeutic applications, and the rising number of research efforts to produce cutting-edge treatment technologies are some of the factors propelling the growth of the neuroendocrine tumor therapy market.
According to a statement released by Bristol-Myers Squibb Company in February 2021, the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) and Cabometyx (cabozantinib) as the first-line treatments for people with advanced renal cell carcinoma (RCC). If the company was approved, it would conduct extensive clinical trials, distribute medicines globally, raise funds, and do additional research. It would lead to a favorable expansion of the market.
The U.S. Food and Drug Administration issued a Complete Response Letter ("CRL") regarding the New Drug Application ("NDA") for surufatinib, which is indicated for the treatment of pancreatic ("pNETs") and extra-pancreatic (non-pancreatic, "epNETs") neuroendocrine tumours ("NETs"), to HUTCHMED Limited, a China-based company that develops, produces, and sells pharmaceutical products.
Key players
Novartis Sanofi Pfizer Genentech Roche AbbVie Johnson & Johnson Celgene BMS Amgen1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Product Outlook
By Site Outlook
By End-use
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.